Nitrome Biosciences
Manufacturing · Mississippi, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Jackson, Mississippi, United StatesPhone Number
(415) 310-1058Website
www.nitromebiosciences.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Nitrome Biosciences
Nitrase Therapeutics specializes in the development of novel therapeutics through its proprietary NITROME Platform, which focuses on the biology of nitrases and their role in various diseases. The company identifies new nitrases and their nitro-substrates to unlock their therapeutic potential. Their innovative approach aims to address a wide range of diseases, including Parkinson's disease. Nitrase Therapeutics is dedicated to pioneering medicines through groundbreaking biological research.Explore more
Popular SearchesNitrome Biosciences IncNitrome BiosciencesNitrome IncNitromebiosciencesSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nitrome Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Nitrome Biosciences
Earning: See what the market has to say on Nitrome Biosciences recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Nitrome Biosciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Nitrome Biosciences launches new products
Click to see if Nitrome Biosciences had a recent Job posting/layoffs
Check out if Nitrome Biosciences is spiking on competitors!
Nitrome Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Nitrome Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Nitrome Biosciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Nitrome Biosciences
Compare insights from companies similar to Nitrome Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Nitrome Biosciences
$5.4M
11-50
Private
$38M
2017
N/A
Company Profile Activity
Activity Insights
Nitrome Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nitrome Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nitrome Biosciences.
Nitrome Biosciences financials insights
Gather financial insights about Nitrome Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$38M
Nitrome Biosciences Tech Stack
A closer look at the technologies used by Nitrome Biosciences
Nitrome Biosciences News & Media
Nitrome Biosciences Appoints Pierre Beaurang, Ph.D., as Chief Executive Officer, Expands Series
SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc. (formerly Nitrome Biosciences), a biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, aNitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson
Nitrome SAB composed of esteemed experts and key scientific thought leaders in neurobiology and drug development Nitrome SAB composed of esteemed experts and key scientific thought leaders in neurobiology and drug developmentNitrome Biosciences Appoints Industry Veteran Perry Karsen as Executive Chairman of the Board of Directors
SAN FRANCISCO, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to target Parkinson’s disease and many other age-related and inflammation disorders, today announced that it has appointed Perry Karsen, a seasoned leader with 35 years of life sciences experience, as executive chairman of its board of directors.Funding Roundup: Company creating 'digital twins' for clinical trials raises $12M
Unlearn.AI, a comapny using machine learning to generate control patients for clinical trials, raised a $12 million series A round. Several other startups shared funding news this week.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Nitrome Biosciences
Sign Up For FreeTo access detailed company insights
Nitrase Therapeutics specializes in the development of novel therapeutics through its proprietary NITROME Platform, which focuses on the biology of nitrases and their role in various diseases. The company identifies new nitrases and their nitro-substrates to unlock their therapeutic potential. Their innovative approach aims to address a wide range... Read More
